Silo Pharma raises $4M in placement, with $7.7M more tied to warrants
What's the deal? Silo PharmaDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed developmental-stage biopharmaceutical company, has raised roughly $4 million in a private placement priced at-the-market under Nasdaq rules. The Sarasota, Florida company sold 619,965 shares (or pre-funded warrants) at $6.452 each, plus two tranches of warrants exercisable immediately at $6.21. H.C. WainwrightDealroom has a profile for this one. Try Dealroom → & Co. acted as exclusive placement agent.
The fine print: The $4 million is upfront money. If the Series A-3 and short-term Series A-4 warrants are fully exercised for cash, Silo could collect roughly $7.7 million more — bringing potential total gross proceeds to about $11.7 million.
What's the endgame? Silo focuses on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical Alzheimer's asset. The company intends to use the net proceeds for working capital and general corporate purposes.
What could go wrong? The extra $7.7 million is far from guaranteed. Silo itself cautioned that no assurance can be given that any warrants will be exercised, or that it will receive cash from them. The offering was expected to close on or about July 10, 2026, subject to customary conditions.
The signal: The at-the-market pricing and warrant-heavy structure are typical of small-cap biotech firms stretching a modest raise for extended runway. For a developmental-stage company still years from revenue, the deal buys time to advance early clinical programs without committing to a larger dilutive round.
Read more: GlobeNewswire
Image credit: Generated with Gemini
